C. S. Pramesh Has Been Elected UICC President-Elect for the 2026–2028 Term
FDA Grants Accelerated Approval: Dostarlimab for MSI-H/dMMR Locally Advanced Rectal Cancer
A Defining Moment for Cancer Immunotherapy During ESMO 2026 - Agenus
Revolution Medicines Begins Phase 3 RASolve 308 Trial of Zoldonrasib in RAS G12D Non-squamous NSCLC
ESMO 2026: 5 Phase III Immunotherapy Trials to Watch
RASolve 308: Phase III Trial Tests Zoldonrasib With Pembrolizumab and Chemotherapy in First-Line RAS G12D NSCLC
Bari, 1943: The Disaster That Changed Cancer Treatment
Tattoos and Cancer: Is There a Link to Skin Cancer and Lymphoma?
OncoDaily IO is the dedicated immuno-oncology platform of OncoDaily, focused on the rapidly evolving science and clinical practice of cancer immunotherapy. It covers the full spectrum of immuno-oncology, including immune checkpoint blockade, cellular therapies, therapeutic cancer vaccines, antibody-based strategies, oncolytic viruses, next-generation immunomodulatory approaches, tumor microenvironment, immune biomarkers, neoantigens, treatment response and resistance, and personalized immunotherapy. Through OncoDaily IO, readers can follow the latest clinical trials, pivotal studies, translational research, regulatory decisions, emerging therapies, major congress highlights, and interviews with leading international experts advancing cancer prevention, control, and treatment through immunotherapy.
